These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 30949827)

  • 1. Effectiveness and side effects of psychopharmacotherapy in individuals with 22q11.2 deletion syndrome with comorbid psychiatric disorders: a systematic review.
    Mosheva M; Korotkin L; Gur RE; Weizman A; Gothelf D
    Eur Child Adolesc Psychiatry; 2020 Aug; 29(8):1035-1048. PubMed ID: 30949827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effectiveness and tolerability of pharmacotherapy for psychosis in 22q11.2 Deletion Syndrome: A systematic review.
    Tanham M; Chen R; Warren N; Heussler H; Scott JG
    Aust N Z J Psychiatry; 2024 May; 58(5):393-403. PubMed ID: 38383990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The feasibility and safety of S-adenosyl-L-methionine (SAMe) for the treatment of neuropsychiatric symptoms in 22q11.2 deletion syndrome: a double-blind placebo-controlled trial.
    Green T; Steingart L; Frisch A; Zarchi O; Weizman A; Gothelf D
    J Neural Transm (Vienna); 2012 Nov; 119(11):1417-23. PubMed ID: 22678699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stimulant treatment effectiveness, safety and risk for psychosis in individuals with 22q11.2 deletion syndrome.
    Basel D; Mosheva M; Maeder J; Schneider M; Shani S; Weinberger R; Eliez S; Gothelf D
    Eur Child Adolesc Psychiatry; 2022 Sep; 31(9):1367-1375. PubMed ID: 33871687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effectiveness and Safety of Antipsychotic and Antidepressant Medications in Individuals with 22q11.2 Deletion Syndrome.
    Dori N; Green T; Weizman A; Gothelf D
    J Child Adolesc Psychopharmacol; 2017 Feb; 27(1):83-90. PubMed ID: 26131914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Education and employment trajectories from childhood to adulthood in individuals with 22q11.2 deletion syndrome.
    Mosheva M; Pouillard V; Fishman Y; Dubourg L; Sofrin-Frumer D; Serur Y; Weizman A; Eliez S; Gothelf D; Schneider M
    Eur Child Adolesc Psychiatry; 2019 Jan; 28(1):31-42. PubMed ID: 29934817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attention Deficit Hyperactivity Disorder Symptoms and Psychosis in 22q11.2 Deletion Syndrome.
    Niarchou M; Calkins ME; Moore TM; Tang SX; McDonald-McGinn DM; Zackai EH; Emanuel BS; Gur RC; Gur RE
    Schizophr Bull; 2018 Jun; 44(4):824-833. PubMed ID: 29040797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Neurocognitive and psychiatric management of the 22q11.2 deletion syndrome].
    Demily C; Rossi M; Schneider M; Edery P; Leleu A; d'Amato T; Franck N; Eliez S
    Encephale; 2015 Jun; 41(3):266-73. PubMed ID: 25523123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attention deficit hyperactivity disorder symptoms as antecedents of later psychotic outcomes in 22q11.2 deletion syndrome.
    Niarchou M; Chawner SJRA; Fiksinski A; Vorstman JAS; Maeder J; Schneider M; Eliez S; Armando M; Pontillo M; Vicari S; McDonald-McGinn DM; Emanuel BS; Zackai EH; Bearden CE; Shashi V; Hooper SR; Owen MJ; Gur RE; Wray NR; van den Bree MBM; Thapar A;
    Schizophr Res; 2019 Feb; 204():320-325. PubMed ID: 30093352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifying patterns of anxiety and depression in children with chromosome 22q11.2 deletion syndrome: comorbidity predicts behavioral difficulties and impaired functional communications.
    Stephenson DD; Beaton EA; Weems CF; Angkustsiri K; Simon TJ
    Behav Brain Res; 2015 Jan; 276():190-8. PubMed ID: 24906195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse effects of antipsychotic medication in patients with 22q11.2 deletion syndrome: A systematic review.
    de Boer J; Boot E; van Gils L; van Amelsvoort T; Zinkstok J
    Am J Med Genet A; 2019 Nov; 179(11):2292-2306. PubMed ID: 31407842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-pharmacological treatment of psychiatric disorders in individuals with 22q11.2 deletion syndrome; a systematic review.
    Buijs PCM; Bassett AS; Boot E
    Am J Med Genet A; 2018 Aug; 176(8):1742-1747. PubMed ID: 29363845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deep psychophysiological phenotyping of adolescents and adults with 22q11.2 deletion syndrome: a multilevel approach to defining core disease processes.
    Parker DA; Cubells JF; Imes SL; Ruban GA; Henshey BT; Massa NM; Walker EF; Duncan EJ; Ousley OY
    BMC Psychiatry; 2023 Jun; 23(1):425. PubMed ID: 37312091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative study of the neuropsychiatric and neurocognitive phenotype in two microdeletion syndromes: velocardiofacial (22q11.2 deletion) and Williams (7q11.23 deletion) syndromes.
    Zarchi O; Diamond A; Weinberger R; Abbott D; Carmel M; Frisch A; Michaelovsky E; Gruber R; Green T; Weizman A; Gothelf D
    Eur Psychiatry; 2014 May; 29(4):203-10. PubMed ID: 24054518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The dimensional structure of psychopathology in 22q11.2 Deletion Syndrome.
    Niarchou M; Moore TM; Tang SX; Calkins ME; McDonald-McGuinn DM; Zackai EH; Emanuel BS; Gur RC; Gur RE
    J Psychiatr Res; 2017 Sep; 92():124-131. PubMed ID: 28433949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated Proinflammatory Markers in 22q11.2 Deletion Syndrome Are Associated With Psychosis and Cognitive Deficits.
    Mekori-Domachevsky E; Taler M; Shoenfeld Y; Gurevich M; Sonis P; Weisman O; Weizman A; Gothelf D
    J Clin Psychiatry; 2017; 78(9):e1219-e1225. PubMed ID: 29141125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and incidence of psychotic disorders in 22q11.2 deletion syndrome: a meta-analysis.
    Provenzani U; Damiani S; Bersano I; Singh S; Moschillo A; Accinni T; Brondino N; Oliver D; Fusar-Poli P
    Int Rev Psychiatry; 2022; 34(7-8):676-688. PubMed ID: 36786112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Negative subthreshold psychotic symptoms distinguish 22q11.2 deletion syndrome from other neurodevelopmental disorders: A two-site study.
    Mekori-Domachevsky E; Guri Y; Yi J; Weisman O; Calkins ME; Tang SX; Gross R; McDonald-McGinn DM; Emanuel BS; Zackai EH; Zalsman G; Weizman A; Gur RC; Gur RE; Gothelf D
    Schizophr Res; 2017 Oct; 188():42-49. PubMed ID: 28041919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical presentation of attention deficit-hyperactivity disorder (ADHD) in children with 22q11.2 deletion syndrome.
    Niarchou M; Martin J; Thapar A; Owen MJ; van den Bree MB
    Am J Med Genet B Neuropsychiatr Genet; 2015 Dec; 168(8):730-8. PubMed ID: 26400629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cognitive behavioral therapy in 22q11.2 microdeletion with psychotic symptoms: What do we learn from schizophrenia?
    Demily C; Franck N
    Eur J Med Genet; 2016 Nov; 59(11):596-603. PubMed ID: 27639442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.